Journal of Neural Transmission

, Volume 119, Issue 4, pp 455–456 | Cite as

CSF biomarkers in different phenotypes of Parkinson disease

Movement Disorders - Short communication

Abstract

CSF biomarker studies were performed in 6 patients each with tremor-dominant (TD) and non-tremor-dominant (NT) Parkinson disease (PD) patients, 27 Alzheimer disease (AD) and 17 age-matched controls. In both NT-PD and AD patients total tau levels and the cortex tau/Aβ-42 were significantly increased compared to both TD-PD patients and controls (p < 0.01). These data in a small cohort confirm previous studies, corroborating the opinion that CSF levels of tau protein and the index total-tau/Aβ-42 may be potential markers of the severity of neurodegeneration in PD.

Keywords

Parkinson disease Clinical phenotypes CSF biomarkers Total-tau/Aβ-42 

References

  1. Alves G, Bronnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E (2010) CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson’s disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 81:1080–1086PubMedCrossRefGoogle Scholar
  2. Brunnström H, Rawshani N, Zetterberg H, Blennow K, Minthon L, Passant U, Englund E (2010) Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses. Alzheimers Dement 6:104–109PubMedCrossRefGoogle Scholar
  3. Clark CM, Davatzikos C, Borthakur A, Newberg A, Leight S, Lee VM, Trojanowski JQ (2008) Biomarkers for early detection of Alzheimer pathology. Neurosignals 16:11–18PubMedCrossRefGoogle Scholar
  4. Compta Y, Marti MJ, Ibarretxe-Bilbao N, Junque C, Valldeoriola F, Munoz E, Ezquerra M, Rios J, Tolosa E (2009) Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson’s disease. Mov Disord 24:2203–2210PubMedCrossRefGoogle Scholar
  5. de Souza LC, Chupin M, Lamari F, Jardel C, Leclercq D, Colliot O, Lehericy S, Dubois B, Sarazin M (2011) CSF tau markers are correlated with hippocampal volume in Alzheimer’s disease. Neurobiol Aging. doi: 10.1016/j.neurobiolaging.2011.1002.1022 (in print)
  6. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedCrossRefGoogle Scholar
  7. Jellinger KA (2010) Neurochemical biomarkers in the differential diagnosis of movement disorders. Mov Disord 25:500PubMedCrossRefGoogle Scholar
  8. Jellinger KA, Mizuno Y (2003) Parkinson disease. In: Dickson DW (ed) Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. ISN Neuropath Press, Basel, pp 159–187Google Scholar
  9. Leverenz JB, Watson GS, Shofer J, Zabetian CP, Zhang J, Montine TJ (2011) Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson’s disease. Parkinsonism Relat Disord 17:61–64PubMedCrossRefGoogle Scholar
  10. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944PubMedGoogle Scholar
  11. Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, Chung KA, Kim H, Galasko DR, Jankovic J, Zabetian CP, Leverenz JB, Zhang J (2010) CSF Abeta(42) and tau in Parkinson’s disease with cognitive impairment. Mov Disord 25:2682–2685PubMedCrossRefGoogle Scholar
  12. Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D’Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P (2008) Cerebrospinal fluid biomarkers in Parkinson’s disease with dementia and dementia with Lewy bodies. Biol Psychiatry 64:850–855PubMedCrossRefGoogle Scholar
  13. Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B, Tambasco N, Eusebi P, Rossi A, Onofrj M, Padovani A, Calabresi P, El-Agnaf O (2011) Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson’s disease and degenerative dementias. Mov Disord. doi: 10.1002/mds.23670 (in print)
  14. Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson’s disease. J Neuropathol Exp Neurol 50:743–755PubMedCrossRefGoogle Scholar
  15. Prikrylova Vranova H, Mares J, Nevrly M, Stejskal D, Zapletalova J, Hlustik P, Kanovsky P (2010) CSF markers of neurodegeneration in Parkinson’s disease. J Neural Transm 117:1177–1181PubMedCrossRefGoogle Scholar
  16. Prikrylova Vranova H, Mares J, Hlustik P, Nevrly M, Stejskal D, Zapletalova J, Obereigneru R, Kanovsky P (2011) Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson’s disease. J Neural Transm. doi: 10.1007/s00702-00011-00708-00704 (in print)
  17. Riverol M, Lopez OL (2011) Biomarkers in Alzheimer’s disease. Front Neurol 2:46. doi: 10.3389/fneur.2011.00046 PubMedGoogle Scholar
  18. Rösler N, Wichart I, Jellinger KA (2001) Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer’s disease patients. J Neural Transm 108:231–246PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.WeinAustria

Personalised recommendations